SG Urges Justices To Hear Hikma’s ‘Skinny Label’ Patent Case
By Editorial Team
The U.S. solicitor general has urged the U.S. Supreme Court to hear Hikma Pharmaceuticals Inc.’s appeal of a decision reviving a patent suit involving its “skinny label” on a generic heart drug. The solicitor general stated that the ruling puts the availability of lower-cost generics at risk.
Hikma Pharmaceuticals Inc. is seeking the Supreme Court’s review after a lower court’s decision revived a patent lawsuit related to its generic heart drug with a “skinny label.” The U.S. solicitor general has now recommended that the Supreme Court take up the case to address the implications of the ruling on the availability of affordable generic medications.
The case revolves around Hikma’s generic heart drug, which uses a “skinny label” to indicate that it is only intended for certain uses that do not infringe on a patented method of treatment. The lower court’s decision raised concerns about the potential impact on the market for lower-cost generics if such labeling practices are restricted.
The solicitor general’s recommendation comes as a significant development in the ongoing legal battle between Hikma Pharmaceuticals Inc. and the patent holders. The Supreme Court’s decision to hear the case could have far-reaching implications for the pharmaceutical industry and the availability of affordable medications for consumers.
Stay tuned for further updates on this important patent case as it progresses through the legal system.
